Everolimus for the treatment of uveitis refractory to cyclosporine A: A pilot study

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 251, Issue 1, 2013, Pages 143-152

  Heiligenhaus, Arnd ^a,b   Zurek Imhoff, Beatrix ^a   Roesel, Martin ^a   Hennig, Maren ^a   Rammrath, Daniela ^a   Heinz, Carsten ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b ST FRANZISKUS HOSPITAL   (Germany)

Author keywords

Clinical trial; Cyclosporine A; Everolimus; Immunosuppression; mTOR inhibitor; Regulatory T cells; Uveitis

Indexed keywords

ALPHA2A INTERFERON; AZATHIOPRINE; CD3 ANTIGEN; CD4 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN A; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ALPHA; METHOTREXATE; PREDNISOLONE; PREDNISONE; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; FLAME PHOTOMETRY; HUMAN; HUMAN CELL; HYPERTENSION; INFECTION; MALE; OPEN STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; RECURRENT DISEASE; RETINA MACULA CYSTOID EDEMA; SIDE EFFECT; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY;

ADULT; CHRONIC DISEASE; CYCLOSPORINE; FEMALE; FLOW CYTOMETRY; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PHOTOMETRY; PILOT PROJECTS; PROSPECTIVE STUDIES; RECURRENCE; SIROLIMUS; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY; YOUNG ADULT;

EID: 84872323723     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-012-2163-9     Document Type: Article

References (49)

1. Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of uveitis nomenclature (SUN) working group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140:509-516
2. Vidovic-Valentincic N, Kraut A, Hawlina M, Stunf S, Rothova A (2009) Intermediate uveitis: long-term course and visual outcome. Br J Ophthalmol 93:477-480
3. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A (1996) Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 80:332-336
4. Rothova A, Berendschot TT, Probst K, van Kooij B et al (2004) Birdshot chorioretinopathy: long-term manifestations and visual prognosis. Ophthalmology 111:954-959
5. Murphy CC, Greiner K, Plskova J, Frost NA, Forrester JV, Dick AD (2007) Validity of using vision-related quality of life as a treatment end point in intermediate and posterior uveitis. Br J Ophthalmol 91:154-156
6. Miserocchi E, Modorati G, Mosconi P, Colucci A, Bandello F (2010) Quality of life in patients with uveitis on chronic systemic immunosuppressive treatment. Ocul Immunol Inflamm 18:297-304
7. Caspi R (2008) Autoimmunity in the immune privileged eye: pathogenic and regulatory T cells. Immunol Res 42:41-50
8. Jabs DA, Akpek EK (2005) Immunosuppression for posterior uveitis. Retina 25:1-18
9. Chen YB, Sun YA, Gong JP (2008) Effects of rapamycin in liver transplantation. Hepatobiliary Pancreat Dis Int 7:25-28
10. Granger DK, Cromwell JW, Chen YB, Goswitz JJ, Morrow DT, Beierle FA, Sehgal SN, Canafax DM, Matas AJ (1995) Prolongation of renal allograft survival in a large animal model by oral rapamycin monotherapy. Transplantation 59:183-186
11. Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P, Touraine JL, Claesson K, Campistol JM, Durand D, Wramner L, Brattström C, Charpentier B (1999) Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 67:1036-1042
12. Kahan BD (1997) Sirolimus: a new agent for clinical renal transplantation. Transplant Proc 29:48-50
13. BenEzra D, Cohen E, Rakotomalala M, de Courten C, Harris W, Chajek T, Friedman G, Matamoros N (1988) Treatment of endogenous uveitis with cyclosporine A. Transplant Proc 20:122-127
14. Nussenblatt RB, Palestine AG, Chan CC, Stevens G Jr, Mellow SD, Green SB (1991) Randomized double masked study of cyclosporine compared to prednisone in the treatment of endogenous uveitis. Am J Ophthalmol 112:138-146
15. Allison AC (2000) Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology 47:63-83
16. Halloran PF (2004) Immunosuppressive drugs for kidney transplantation. N Engl J Med 351:2715-2729
17. Kekäläinen E, Tuovinen H, Joensuu J, Gylling M, Franssila R, Pöntynen N, Talvensaari K, Perheentupa J, Miettinen A, Arstila TP (2007) A defect of regulatory T cells in patients with autoimmune polyendocrinopathy- candidiasis-ectodermal dystrophy. J Immunol 178:1208-1215
18. Valencia X, Yarboro C, Illei G, Lipsky PE (2007) Deficient CD4 + CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 178:2579-2588
19. Schuler W, Sedrani R, Cottens S, Häberlin B, Schulz M, Schuurman HJ, Zenke G, Zerwes HG, Schreier MH (1997) SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 64:36-42
20. Chen J (2004) Novel regulatory mechanisms of mTOR signaling. Curr Top Microbiol Immunol 279:245-257
21. Schuurman HJ, Cottens S, Fuchs S, Joergensen J, Meerloo T, Sedrani R, Tanner M, Zenke G, Schuler W (1997) SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation 64:32-35
22. Haxhinasto S, Mathis D, Benoist C (2008) The AKT-mTOR axis regulates de novo differentiation of CD4 + Foxp3+ cells. J Exp Med 205:565-574
23. Kang J, Huddleston SJ, Fraser JM, Khoruts A (2008) De novo induction of antigen-specific CD4 + CD25 + Foxp3+ regulatory T cells in vivo following systemic antigen administration accompanied by blockade of mTOR. J Leukoc Biol 83:1230-1239
24. Sauer S, Bruno L, Hertweck A, Leleu M, Spivakov M, Knight ZA, Cobb BS, Cantrell D, O'Connor E, Shokat KM, Fisher AG, Merkenschlager M (2008) T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A 105:7797-7802
25. Zeiser R, Leveson-Gower DB, Zambricki EA, Kambham N, Beilhack A, Loh J, Hou JZ, Negrin RS (2008) Differential impact of mammalian target of rapamycin inhibition on CD4 + CD25 + Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood 111:453-462
26. Schuurman HJ, Ringers J, Schuler W, Slingerland W, Jonker M (2000) Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation. Transplantation 69:737-742
27. Schuurman HJ, Schuler W, Ringers J, Jonker M (1998) The macrolide SDZ RAD is efficacious in a nonhuman primate model of allotransplantation. Transplant Proc 30:2198-2199
28. Gullestad L, Mortensen SA, Eiskjoer H, Riise GC, Mared L, Bjortuft O, Ekmehag B, Jansson K, Simonsen S, Gude E, Rundqvist B, Fagertun HE, Solbu D, Iversen M (2010) Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial. Transplantation 90:1581-1589
29. Crowe A, Bruelisauer A, Duerr L, Guntz P, Lemaire M (1999) Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. Drug Metab Dispos 27:627-632
30. Lieberthal W, Fuhro R, Andry CC, Rennke H, Abernathy VE, Koh JS, Valeri R, Levine JS (2001) Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol 281:693-706
31. Tenderich G, Fuchs U, Zittermann A, Muckelbauer R, Berthold HK, Koerfer R (2007) Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients. Clin Transplant 21:536-543
32. Bruyn GAW, Tate G, Caeiro F, Maldonado-Cocco J, Westhovens R, Tannenbaum H, Bell M, Forre O, Bjorneboe O, Tak PP, Abeywickrama KH, Bernhardt P, van Riel PL, RADD Study Group (2008) Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study. Ann Rheum Dis 67:1090-1095
33. Ladas JG, Wheeler NC, Morhun PJ, Rimmer SO, Holland GN (2005) Laser flare-cell photometry: methodology and clinical applications. Surv Ophthalmol 50:27-47
34. Gonzales CA, Ladas JG, Davis JL, Feuer WJ, Holland GN (2001) Relationships between laser flare photometry values and complications of uveitis. Arch Ophthalmol 119:1763-1769
35. Gutfleisch M, Spital G, Mingels A, Pauleikhoff D, Lommatzsch A, Heiligenhaus A (2007) Pars plana vitrectomy with intravitreal triamcinolone: effect on uveitic cystoid macular oedema and treatment limitations. Br J Ophthalmol 91:345-348
36. Costa RA, Calucci D, Skaf M, Cardillo JA, Castro JC, Melo LA Jr, Martins MC, Kaiser PK (2004) Optical coherence tomography 3: automatic delineation of the outer neural retinal boundary and its influence on retinal thickness measurements. Investig Ophthalmol Vis Sci 45:2399-2406
37. Sandberg MA, Brockhurst RJ, Gaudio AR, Berson EL (2005) The association between visual acuity and central retinal thickness in retinitis pigmentosa. Invest Ophthalmol Vis Sci 46:3349-3354
38. Olsen TW, Benegas NM, Joplin AC, Evangelista T, Mindrup EA, Holland EJ (1994) Rapamycin inhibits corneal allograft rejection and neovascularization. Arch Ophthalmol 112:1471-1475
39. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8:128-135
40. Roberge FG, Xu D, Chan CC, de Smet MD, Nussenblatt RB, Chen H (1993) Treatment of autoimmune uveoretinitis in the rat with rapamycin, an inhibitor of lymphocyte growth factor signal transduction. Curr Eye Res 12:197-203
41. Martin DF, DeBarge LR, Nussenblatt RB, Chan CC, Roberge FG (1995) Synergistic effect of rapamycin and cyclosporine A in the treatment of experimental autoimmune uveoretinitis. J Immunol 154:922-927
42. Shanmuganathan VA, Casely EM, Rai D, Powell RJ, Joseph A, Amoaku WM, Dua HS (2005) The efficacy of sirolimus in the treatment of patients with refractory uveitis. Br J Ophthalmol 89:666-669
43. Battaglia M, Stabilini A, Roncarolo MG (2005) Rapamycin selectively expands CD4 + CD25 + Foxp3+ regulatory T cells. Blood 105:4743-4748
44. San Segundo D, Fernandez-Fresnedo G, Gago M, Beares I, Ruiz-Criado J, González M, Ruiz JC, Gómez-Alamillo C, Arias M, López-Hoyos M (2010) Number of peripheral regulatory T cells and lymphocyte activation at 3 months after conversion to mTOR inhibitory therapy. Transplant Proc 42:2871-2873
45. Keino H, Takeuchi M, Usui Y, Hattori T, Yamakawa N, Kezuka T, Sakai JI, Usui M (2007) Supplementation of CD4 + CD25+ regulatory T cells suppresses experimental autoimmune uveoretinitis. Br J Ophthalmol 91:105-110
46. Bueno OF, Brandt EB, Rothenberg ME, Molkentin JD (2002) Defective T cell development and function in calcineurin A beta-deficient mice. Proc Natl Acad Sci U S A 99:9398-9403
47. Fontenot JD, Rasmussen JP, Gavin M, Rudensky AY (2005) A function for interleukin-2 in Foxp3-expressing regulatory T cells. Nat Immunol 6:1142-1151
48. D'Cruz LM, Klein L (2005) Development and function of agonist-induced CD25 + Foxp3+ regulatory T cells in the absence of interleukin 2-signaling. Nat Immunol 6:1152-1159
49. Baan CC, van der Mast BJ, Klepper M, Mol WM, Peeters AM, Korevaar SS, Balk AH, Weimar W (2005) Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of Foxp3 in human T cells. Transplantation 80:110-117